| SARS-CoV-2 symptom history | Total | SARS-CoV-2 serological status (n = 692) | p-Value | |
| Positive (%) | Negative (%) | |||
| Contact with SARS-CoV-2 infected person | 48 (6.8) | 14 (29.2) | 34 (70.8) | 0.467 |
| Sore Throat | 45 (6.4) | 17 (37.9) | 28 (62.2) | 0.576 |
| Runny Nose (Rhinorrhea) | 131 (18.5) | 39 (29.8) | 92 (70.2) | 0.261 |
| Cough | 95 (13.4) | 28 (29.5) | 47 (70.5) | 0.320 |
| Shortness of breath (Dyspnea) | 19 (2.7) | 5 (26.3) | 14 (73.7) | 0.476 |
| Other respiratory symptoms | 7 (1.0) | 1 (14.3) | 6 (85.7) | 0.433 |
| Chills | 21 (3.0) | 12 (57.1) | 9 (42.9) | 0.023* |
| Vomiting | 10 (1.4) | 3 (30.0) | 7 (70.0) | 1.000 |
| Nausea | 26 (3.7) | 10 (38.5) | 16 (61.5) | 0.621 |
| Diarrhea | 42 (5.9) | 12 (30.9) | 29 (69.1) | 0.671 |
| Headache | 113 (16.0) | 44 (38.9) | 69 (61.1) | 0.222 |
| Rash | 27 (3.8) | 8 (29.6) | 19 (70.4) | 0.620 |
| Conjunctivitis | 9 (1.3) | 3 (33.3) | 6 (66.7) | 1.000 |
| Muscle aches | 35 (5.0) | 16 (45.7) | 19 (54.3) | 0.132 |
| Joint aches (Myalgia) | 42 (5.9) | 16 (38.1) | 26 (61.9) | 0.559 |
| Loss of appetite | 28 (4.0) | 10 (35.7) | 18 (64.3) | 0.841 |
| Loss of smell (Anosmia) | 10 (1.4) | 4 (40.0) | 6 (60.0) | 0.685 |
| Loss of Test (Ageusia) | 13 (1.8) | 6 (46.1) | 7 (53.8) | 0.349 |
| Nose bleed | 9 (1.3) | 3 (33.3) | 6 (66.7) | 1.000 |
| Fatigue | 18 (2.5) | 10 (55.6) | 8 (44.4) | 0.050 |
| Seizures | 8 (1.1) | 2 (25.0) | 6 (70.0) | 0.723 |
| Altered Consciousness | 6 (0.8) | 3 (50.0) | 3 (50.0) | 0.414 |
| Other Neurological signs | 10 (1.4) | 3 (30.0) | 7 (70.0) | 1.000 |
| Other symptoms | 6 (0.8) | 3 (50.0) | 3 (50.0) | 0.414 |
| Participants’ reported health outcome |
|
|
|
|
| Seeking medical attention | 47 (6.6) | 16 (34.0) | 31 (66.0) | 0.614 |
| Miss school/work | 25 (3.5) | 8 (32.0) | 17 (68.0) | 0.833 |
| Required hospitalization | 34 (4.8) | 11 (32.4) | 23 (67.6) | 0.839 |